The number of COVID-19 vaccination doses administered per 100 people in Australia rose to 243 as of Oct 27 2023. This dataset includes a chart with historical data for Australia Coronavirus Vaccination Rate.

This dataset presents the footprint of the percentage of boys who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2014-2016 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

HPV is a common sexually transmitted infection. It is estimated that more than four out of five people will have an HPV infection at some point in their lives. Although often asymptomatic, HPV infection can cause a wide range of cancers, including cervical cancer, and other conditions such as genital warts. The Australian Government introduced the school-based National HPV Vaccination Program in 2007 for adolescent girls, and extended it to include boys in January 2013. The data were sourced from the National HPV Vaccination Program Register (HPV Register), which is operated by the Victorian Cytology Service. The HPV Register records information about HPV vaccine doses administered under the National HPV Vaccination Program in Australia. The data reported are for girls and boys aged 15 who had received three doses of HPV vaccine by 30 June 2016 (as at 12 August 2017). The Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females and males aged 13 at 30 June 2014 was used for the denominator, as this reflects the eligible population at the time most vaccinations were administered.

\t\t\t\t\t\t\t\t\t\t\t\t\tFor further information about this dataset, visit the data source:Australian Institute of Health and Welfare - HPV immunisation rates in 2015-16 Data Tables.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• These data include boys aged 15 who had received three doses of HPV vaccine by 30 June 2015 and 2016. Any doses administered after that date are not included and therefore the current coverage in this cohort may be higher than reported here. Only vaccinations reported to the National HPV Vaccination Program Register (HPV Register) are included.

• Boys whose courses are considered to be incomplete according to the Chief Medical Officer guidelines and boys who do not wish their details to be recorded on the HPV Register are excluded.

This dataset presents the footprint of the percentage of girls who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2012-2016 and is aggregated to Statistical Area Level 4 (SA4) from the 2011 Australian Statistical Geography Standard (ASGS).

HPV is a common sexually transmitted infection. It is estimated that more than four out of five people will have an HPV infection at some point in their lives. Although often asymptomatic, HPV infection can cause a wide range of cancers, including cervical cancer, and other conditions such as genital warts. The Australian Government introduced the school-based National HPV Vaccination Program in 2007 for adolescent girls, and extended it to include boys in January 2013. The data were sourced from the National HPV Vaccination Program Register (HPV Register), which is operated by the Victorian Cytology Service. The HPV Register records information about HPV vaccine doses administered under the National HPV Vaccination Program in Australia. The data reported are for girls and boys aged 15 who had received three doses of HPV vaccine by 30 June 2016 (as at 12 August 2017). The Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females and males aged 13 at 30 June 2014 was used for the denominator, as this reflects the eligible population at the time most vaccinations were administered.

\t\t\t\t\t\t\t\t\t\t\t\t\tFor further information about this dataset, visit the data source:Australian Institute of Health and Welfare - HPV immunisation rates in 2015-16 Data Tables.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• These data include girls aged 15 who had received three doses of HPV vaccine by 30 June 2013, 2014, 2015 and 2016. Any doses administered after that date are not included and therefore the current coverage in this cohort may be higher than reported here. Only vaccinations reported to the National HPV Vaccination Program Register (HPV Register) are included.

• Girls whose courses are considered to be incomplete according to the Chief Medical Officer guidelines and girls who do not wish their details to be recorded on the HPV Register are excluded.

• Values assigned to "n.p." in the original data have been removed from the data.

JHU Has Stopped Collecting Data As Of 03/10/2023

After three years of around-the-clock tracking of COVID-19 data from around the world, Johns Hopkins has discontinued the Coronavirus Resource Center’s operations.

The site’s two raw data repositories will remain accessible for information collected from 1/22/20 to 3/10/23 on cases, deaths, vaccines, testing and demographics.

Novel Corona Virus (COVID-19) epidemiological data since 22 January 2020. The data is compiled by the Johns Hopkins University Center for Systems Science and Engineering (JHU CCSE) from various sources including the World Health Organization (WHO), DXY.cn, BNO News, National Health Commission of the People’s Republic of China (NHC), China CDC (CCDC), Hong Kong Department of Health, Macau Government, Taiwan CDC, US CDC, Government of Canada, Australia Government Department of Health, European Centre for Disease Prevention and Control (ECDC), Ministry of Health Singapore (MOH), and others. JHU CCSE maintains the data on the 2019 Novel Coronavirus COVID-19 (2019-nCoV) Data Repository on Github.

Fields available in the data include Province/State, Country/Region, Last Update, Confirmed, Suspected, Recovered, Deaths.

On 23/03/2020, a new data structure was released. The current resources for the latest time series data are:

• time_series_covid19_confirmed_global.csv
• time_series_covid19_deaths_global.csv
• time_series_covid19_recovered_global.csv

---DEPRECATION WARNING---
The resources below ceased being updated on 22/03/2020 and were removed on 26/03/2020:

• time_series_19-covid-Confirmed.csv
• time_series_19-covid-Deaths.csv
• time_series_19-covid-Recovered.csv

This dataset corresponds to paper titled "A Mathematical Model for COVID-19 Considering Waning Immunity, Vaccination and Control Measures". In this work we define a modified SEIR model that accounts for the spread of infection during the latent period, infections from asymptomatic or pauci-symptomatic infected individuals, potential loss of acquired immunity, people’s increasing awareness of social distancing and the use of vaccination as well as non-pharmaceutical interventions like social confinement. We estimate model parameters in three different scenarios - in Italy, where there is a growing number of cases and re-emergence of the epidemic, in India, where there are significant number of cases post confinement period and in Victoria, Australia where a re-emergence has been controlled with severe social confinement program. Our result shows the benefit of long term confinement of 50% or above population and extensive testing. With respect to loss of acquired immunity, our model suggests higher impact for Italy. We also show that a reasonably effective vaccine with mass vaccination program can be successful in significantly controlling the size of infected population. We show that for India, a reduction in contact rate by 50% compared to a reduction of 10% in the current stage can reduce death from 0.0268% to 0.0141% of population. Similarly, for Italy we show that reducing contact rate by half can reduce a potential peak infection of 15% population to less than 1.5% of population, and potential deaths from 0.48% to 0.04%. With respect to vaccination, we show that even a 75% efficient vaccine administered to 50% population can reduce the peak number of infected population by nearly 50% in Italy. Similarly, for India, a 0.056% of population would die without vaccination, while 93.75% efficient vaccine given to 30\% population would bring this down to 0.036% of population, and 93.75% efficient vaccine given to 70% population would bring this down to 0.034%.